Callan Capital LLC Lowers Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Callan Capital LLC trimmed its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 22.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,000 shares of the company’s stock after selling 3,400 shares during the period. Callan Capital LLC’s holdings in Tarsus Pharmaceuticals were worth $664,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its position in Tarsus Pharmaceuticals by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company’s stock valued at $449,000 after buying an additional 789 shares during the last quarter. R Squared Ltd purchased a new position in Tarsus Pharmaceuticals in the 4th quarter valued at $53,000. Rhumbline Advisers lifted its holdings in Tarsus Pharmaceuticals by 2.1% in the fourth quarter. Rhumbline Advisers now owns 49,534 shares of the company’s stock valued at $2,743,000 after acquiring an additional 1,019 shares during the period. Franklin Resources Inc. lifted its holdings in Tarsus Pharmaceuticals by 9.3% in the third quarter. Franklin Resources Inc. now owns 12,164 shares of the company’s stock valued at $444,000 after acquiring an additional 1,033 shares during the period. Finally, Legato Capital Management LLC lifted its holdings in Tarsus Pharmaceuticals by 3.4% in the fourth quarter. Legato Capital Management LLC now owns 45,656 shares of the company’s stock valued at $2,528,000 after acquiring an additional 1,496 shares during the period. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Oppenheimer raised their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Barclays raised their target price on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Monday, January 27th. The Goldman Sachs Group raised their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Finally, Guggenheim reissued a “buy” rating on shares of Tarsus Pharmaceuticals in a report on Monday, February 10th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $56.00.

Tarsus Pharmaceuticals Trading Down 1.8 %

NASDAQ:TARS opened at $47.84 on Friday. The company has a market capitalization of $1.83 billion, a PE ratio of -12.56 and a beta of 1.01. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The stock has a fifty day simple moving average of $51.87 and a 200-day simple moving average of $42.61.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.